Svetlana Sosnovtseva

TL;DR: The biological profile of BLyS suggests it is involved in monocyte-driven B cell activation, and its expression on human monocytes could be up-regulated by interferon-gamma.

TL;DR: Results provide further support for an important role for BLyS expressed in myeloid cells in B-cell expansion and antibody responses.

TL;DR: It is shown that APRIL and BLyS can form active heterotrimeric molecules when coexpressed and that circulatingheterotrimers are present in serum samples from patients with systemic immune-based rheumatic diseases.

TL;DR: Systemic administration of BLyS to mice resulted in increased serum IgG, IgA, IgM, and IgE and salivary IgA as well as splenic B cell population expansion and differentiation and a linear pharmacodynamic response was identified, indicating that the response is more sensitive to the duration of dosing than to the cumulative dose.

TL;DR: The possibility that the combination of a BLyS protein antagonist with an agent that targets (helper) T cells may have salutary synergistic effects on autoantibody production in diseases such as systemic lupus erythematosus is raised.